New drug cocktail aims to wipe out Triple-Negative breast cancer before surgery
NCT ID NCT07466303
First seen Mar 13, 2026 · Last updated May 23, 2026 · Updated 12 times
Summary
This study tests whether giving two drugs—serplulimab and trastuzumab rezetecan—before surgery can completely eliminate triple-negative breast cancer in 84 women. Participants will receive the combination as neoadjuvant therapy, and the main goal is to see how many have no cancer left in the breast or lymph nodes at the time of surgery. The trial is for women aged 18–70 with early-stage, untreated triple-negative breast cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the First Affiliated Hospital of the Air Force Medical University
Xi'an, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.